Role of gemcitabine in cancer therapy

Future Oncology 1, 7-17 DOI: 10.1517/14796694.1.1.7

Citation Report

#	Article	IF	CITATIONS
1	Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. Journal of Cancer Research and Clinical Oncology, 2006, 132, 745-755.	2.5	52
2	Phase I Study of Bryostatin 1 and Gemcitabine. Clinical Cancer Research, 2006, 12, 7059-7062.	7.0	22
3	Potentiation of High-LET Radiation by Gemcitabine: Targeting HER2 with Trastuzumab to Treat Disseminated Peritoneal Disease. Clinical Cancer Research, 2007, 13, 1926-1935.	7.0	65
5	Molecular impacts of rapamycin-based drug combinations: Combining rapamycin with gemcitabine or imatinib mesylate (Gleevec) in a human leiomyosarcoma model. International Journal of Oncology, 0, , .	3.3	4
6	Rapid determination of gemcitabine in plasma and serum using reversedâ€phase HPLC. Journal of Separation Science, 2007, 30, 1811-1820.	2.5	35
7	Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature, 2007, 446, 815-819.	27.8	438
8	Cutaneous metastasis as the first clinical manifestation of pancreatic adenocarcinoma: A case treated with gemcitabine. Journal of Dermatology, 2007, 34, 662-664.	1.2	14
9	The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent. Biochemical Pharmacology, 2007, 73, 1548-1557.	4.4	23
10	Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas. Cancer Chemotherapy and Pharmacology, 2008, 62, 647-653.	2.3	20
11	Clofarabine Acts as Radiosensitizer In Vitro and In Vivo by Interfering With DNA Damage Response. International Journal of Radiation Oncology Biology Physics, 2008, 70, 213-220.	0.8	18
12	Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs. Veterinary and Comparative Oncology, 2008, 6, 90-101.	1.8	44
13	The combined effect of fludarabine monophosphate and radiation as well as gemcitabine and radiation on squamous carcinoma tumor cell lines <i>in vitro</i> . International Journal of Radiation Biology, 2008, 84, 643-657.	1.8	7
14	Polyaspartylhydrazide Copolymer-Based Supramolecular Vesicular Aggregates as Delivery Devices for Anticancer Drugs. Biomacromolecules, 2008, 9, 1117-1130.	5.4	33
15	Novel Approaches to Deliver Gemcitabine to Cancers. Current Pharmaceutical Design, 2008, 14, 1124-1137.	1.9	101
16	Modulation of Gemcitabine (2′,2′-Difluoro-2′-Deoxycytidine) Pharmacokinetics, Metabolism, and Bioavailability in Mice by 3,4,5,6-Tetrahydrouridine. Clinical Cancer Research, 2008, 14, 3529-3535.	7.0	55
17	A Pharmacodynamic Model for the Time Course of Tumor Shrinkage by Gemcitabine + Carboplatin in Non–Small Cell Lung Cancer Patients. Clinical Cancer Research, 2008, 14, 4213-4218.	7.0	67
18	S-phase cell-specific modification by gemcitabine of PFGE-analyzed radiation-induced DNA fragmentation and rejoining. International Journal of Radiation Biology, 2008, 84, 770-777.	1.8	3
19	Outpatient Chemotherapy plus Radiotherapy in Sarcomas: Improving Cancer Control with Radiosensitizing Agents. Cancer Control, 2008, 15, 38-46.	1.8	56

		CITATION REPORT	
#	ARTICLE Gemcitabine-Induced Supraventricular Tachycardia, Tumori, 2009, 95, 547-549	IF	CITATIONS
20		1.1	
21	The treatment of metastasis to the femoral neck using percutaneous hollow perforated screws wi cement augmentation. Journal of Bone and Joint Surgery: British Volume, 2009, 91-B, 1078-1082.	th 3.4	18
22	Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. Pharmacogenomics, 2009, 10, 69-80.	1.3	41
23	Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. Annals of Oncolog 2009, 20, 182-187.	y, 1.2	60
24	Strategies to Increase the Oral Bioavailability of Nucleoside Analogs. Current Medicinal Chemistry 2009, 16, 1391-1399.	, 2.4	14
25	Cutaneous vasculitis associated with gemcitabine therapy. Clinical and Experimental Dermatology 2009, 34, 97-99.	, 1.3	6
26	Electrochemical studies and spectroscopic investigations on the interaction of an anticancer drug with DNA and their analytical applications. Journal of Electroanalytical Chemistry, 2009, 636, 93-1	00. <u>3.8</u>	150
27	Drosophila melanogaster deoxyribonucleoside kinase activates gemcitabine. Biochemical and Biophysical Research Communications, 2009, 382, 430-433.	2.1	13
28	<i>In Situ</i> Protein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patient Treated with Gemcitabine-Based Chemotherapy. Cancer Investigation, 2009, 28, 172-180.	.s 1.3	23
29	Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcom non-small cell lung cancer patients. Lung Cancer, 2009, 63, 121-127.	ne in 2.0	59
30	Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme. Cancer Chemotherapy and Pharmacology, 2010, 65, 391-397.	2.3	27
31	Folate-targeted supramolecular vesicular aggregates based on polyaspartyl-hydrazide copolymers the selective delivery of antitumoral drugs. Biomaterials, 2010, 31, 7340-7354.	for 11.4	58
32	Prior splenic irradiation reduces hematologic adverse events during chemotherapy in pancreatic to cancer: a report of a patient with liver cirrhosis. Clinical Journal of Gastroenterology, 2010, 3, 337-342.	ail 0.8	0
33	Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR®: Biodistribution, pharmacokir features and in vivo antitumor activity. Journal of Controlled Release, 2010, 144, 144-150.	etic 9.9	109
34	Cell cycle arrest and apoptosis in <i>TP53</i> subtypes of bladder carcinoma cell lines treated wit cisplatin and gemcitabine. Experimental Biology and Medicine, 2010, 235, 814-824.	h 2.4	39
35	Calcitriol enhances gemcitabine antitumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system. Cell Cycle, 2010, 9, 3094-3101.	2.6	51
36	Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation Nanoscale, 2010, 2, 1521.	n. 5.6	34
37	N6-substituted adenosines. Cytokinin and antitumor activities. Collection of Czechoslovak Chemi Communications, 2011, 76, 1361-1378.	cal 1.0	18

#	Article	IF	CITATIONS
38	Combination Effects of Digalloylresveratrol With Arabinofuranosylcytosine and Difluorodeoxycytidine in Human Leukemia and Pancreatic Cancer Cells. Nucleosides, Nucleotides and Nucleic Acids, 2011, 30, 1190-1196.	1.1	2
39	BOOP as a rare complication of gemcitabine therapy. BMJ Case Reports, 2011, 2011, bcr0420114055-bcr0420114055.	0.5	3
40	A novel N-hydroxy-N′-aminoguanidine derivative inhibits ribonucleotide reductase activity: Effects in human HL-60 promyelocytic leukemia cells and synergism with arabinofuranosylcytosine (Ara-C). Biochemical Pharmacology, 2011, 81, 50-59.	4.4	12
41	Gemcitabine-Induced Acute Myositis in a Patient with Duodenal Cancer. Clinical Oncology, 2011, 23, 492-493.	1.4	4
42	Small molecule inhibitor of the RPA70 N-terminal protein interaction domain discovered using in silico and in vitro methods. Bioorganic and Medicinal Chemistry, 2011, 19, 2589-2595.	3.0	38
43	Towards Tailored Therapy of Glioblastoma Multiforme. Journal of Chemotherapy, 2011, 23, 187-199.	1.5	19
44	Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine. Oncology Reports, 2011, 25, 1683-9.	2.6	11
45	Solitary cerebral metastasis from transitional cell carcinoma after a 14-year remission of urinary bladder cancer treated with gemcitabine: Case report and literature review. , 2012, 3, 82.		18
46	sMEK1 enhances gemcitabine anti-cancer activity through inhibition of phosphorylation of Akt/mTOR. Apoptosis: an International Journal on Programmed Cell Death, 2012, 17, 1095-1103.	4.9	20
47	Electrochemical investigations of an anticancer drug in the presence of sodium dodecyl sulfate as an enhancing agent at carbon paste electrode. Journal of Applied Electrochemistry, 2012, 42, 917-923.	2.9	21
48	SL-01, an oral gemcitabine derivative, inhibited human cancer growth more potently than gemcitabine. Toxicology and Applied Pharmacology, 2012, 262, 293-300.	2.8	7
49	Synergistic Antitumor Activity of Anti-CD25 Recombinant Immunotoxin LMB-2 with Chemotherapy. Clinical Cancer Research, 2012, 18, 152-160.	7.0	19
50	Effects of 12-O-tetradecanoylphorbol-13-acetate in combination with gemcitabine on Panc-1 pancreatic cancer cells cultured in vitro or Panc-1 tumors grown in immunodeficient mice. International Journal of Oncology, 2012, 41, 2269-2275.	3.3	5
51	Toxicogenomic activity of gemcitabine in two TP53-mutated bladder cancer cell lines: special focus on cell cycle-related genes. Molecular Biology Reports, 2012, 39, 10373-10382.	2.3	16
52	Synthesis and Biological Evaluation of Oral Prodrugs Based on the Structure of Gemcitabine. Chemical Biology and Drug Design, 2012, 80, 479-488.	3.2	5
53	Pharmacokinetics and metabolism of SL-01, a prodrug of gemcitabine, in rats. Cancer Chemotherapy and Pharmacology, 2013, 71, 1541-1550.	2.3	7
54	Functionalized magnetic nanoparticles as vehicles for the delivery of the antitumor drug gemcitabine to tumor cells. Physicochemical in vitro evaluation. Materials Science and Engineering C, 2013, 33, 1183-1192.	7.3	33
55	BLU enhances the effects of anti-angiogenic activity in combination with gemcitabine-based chemotherapeutic agents. International Journal of Biochemistry and Cell Biology, 2013, 45, 1236-1245.	2.8	7

#	Article	IF	CITATIONS
56	Electro-oxidation and determination of gemcitabine hydrochloride, an anticancer drug at gold electrode. Journal of Industrial and Engineering Chemistry, 2013, 19, 1933-1938.	5.8	22
57	Sensitization of Tumor to 212Pb Radioimmunotherapy by Gemcitabine Involves Initial Abrogation of G2 Arrest and Blocked DNA Damage Repair by Interference With Rad51. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1119-1126.	0.8	25
58	Digalloylresveratrol, a novel resveratrol analog inhibits the growth of human pancreatic cancer cells. Investigational New Drugs, 2013, 31, 1115-1124.	2.6	14
59	Expression levels of ERCC1 and RRM1 mRNA and clinical outcome of advanced non-small cell lung cancer. Pakistan Journal of Medical Sciences, 2013, 29, 1158-61.	0.6	11
60	Gemcitabine-Associated "Pseudocellulitis―and "Pseudosepsis― American Journal of Therapeutics, 2013, 20, 118-120.	0.9	14
61	Evaluation of Platinum Chemotherapy in Combination with HER2-Targeted α-Particle Radiation. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 441-449.	1.0	22
62	Gemcitabine therapyâ€associated cutaneous vasculitis with a polyarteritis nodosaâ€like pattern. International Journal of Dermatology, 2013, 52, 1029-1031.	1.0	8
64	Human Concentrative Nucleoside Transporter 3 Transfection with Ultrasound and Microbubbles in Nucleoside Transport Deficient HEK293 Cells Greatly Increases Gemcitabine Uptake. PLoS ONE, 2013, 8, e56423.	2.5	25
65	Genetic Instability in Normal-Appearing and Tumor Urothelium Cells and the Role of the TP53 Gene in the Toxicogenomic Effects of Antineoplastic Drugs. , 2013, , .		0
66	Antimetabolite Treatment for Pancreatic Cancer. Chemotherapy, 2014, 03, .	0.0	18
67	Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer. Genetics and Molecular Research, 2014, 13, 5292-5298.	0.2	6
69	Genetic factors associated with gemcitabine pharmacokinetics, disposition, and toxicity. Pharmacogenetics and Genomics, 2014, 24, 15-25.	1.5	9
70	Current prodrug strategies for improving oral absorption of nucleoside analogues. Asian Journal of Pharmaceutical Sciences, 2014, 9, 65-74.	9.1	38
71	Synthesis and Cytostatic Evaluation of 4- <i>N</i> -Alkanoyl and 4- <i>N-</i> Alkyl Gemcitabine Analogues. Journal of Medicinal Chemistry, 2014, 57, 191-203.	6.4	22
72	Multifunctional polymersomes for cytosolic delivery of gemcitabine and doxorubicin to cancer cells. Biomaterials, 2014, 35, 6482-6497.	11.4	81
73	Engineered Nanoparticles for Drug Delivery in Cancer Therapy. Angewandte Chemie - International Edition, 2014, 53, 12320-12364.	13.8	1,447
74	Downregulating sCLU Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Gemcitabine by Activating the Intrinsic Apoptosis Pathway. Digestive Diseases and Sciences, 2014, 59, 1798-1809.	2.3	16
75	MRE11A and SKP2 genes are associated with the increased cytotoxicity induced by the synergistic effects of cisplatin and gemcitabine in bladder cancer cells. Molecular Biology Reports, 2014, 41, 4613-4621.	2.3	7

#	Article	IF	CITATIONS
76	Gemcitabine Treatment of Rat Soft Tissue Sarcoma with Phosphatidyldiglycerol-Based Thermosensitive Liposomes. Pharmaceutical Research, 2014, 31, 2276-2286.	3.5	50
77	Development of High-Content Gemcitabine PEGylated Liposomes and Their Cytotoxicity on Drug-Resistant Pancreatic Tumour Cells. Pharmaceutical Research, 2014, 31, 2583-2592.	3.5	38
78	Development of a gradient high performance liquid chromatography assay for simultaneous analysis of hydrophilic gemcitabine and lipophilic curcumin using a central composite design and its application in liposome development. Journal of Pharmaceutical and Biomedical Analysis, 2014, 98, 371-378.	2.8	23
79	Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development. Journal of Medicinal Chemistry, 2014, 57, 1531-1542.	6.4	125
80	Dual targeting of heat shock proteins 90 and 70 promotes cell death and enhances the anticancer effect of chemotherapeutic agents in bladder cancer. Oncology Reports, 2014, 31, 2482-2492.	2.6	48
81	Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment. Leukemia Research, 2015, 39, 786-792.	0.8	17
82	Epigallocatechin gallate, ellagic acid, and rosmarinic acid perturb dNTP pools and inhibit de novo DNA synthesis and proliferation of human HL-60 promyelocytic leukemia cells: Synergism with arabinofuranosylcytosine. Phytomedicine, 2015, 22, 213-222.	5.3	32
83	Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy. Gene, 2015, 559, 31-37.	2.2	22
84	Clinical and pharmacogenomic implications of genetic variation in a Southern Ethiopian population. Pharmacogenomics Journal, 2015, 15, 101-108.	2.0	15
85	Ginkgo biloba. , 2016, , 1901-1904.		0
85 86	Ginkgo biloba. , 2016, , 1901-1904. Integrinâ€Targeting Knottin Peptide–Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation. Angewandte Chemie, 2016, 128, 10048-10051.	2.0	0 6
85 86 87	Ginkgo biloba., 2016, , 1901-1904. Integrinâ€Targeting Knottin Peptide–Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation. Angewandte Chemie, 2016, 128, 10048-10051. Sequential culture on biomimetic nanoclay scaffolds forms threeâ€dimensional tumoroids. Journal of Biomedical Materials Research - Part A, 2016, 104, 1591-1602.	2.0	0 6 22
85 86 87 88	Ginkgo biloba., 2016, , 1901-1904. Integrinâ€Targeting Knottin Peptide–Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation. Angewandte Chemie, 2016, 128, 10048-10051. Sequential culture on biomimetic nanoclay scaffolds forms threeâ€dimensional tumoroids. Journal of Biomedical Materials Research - Part A, 2016, 104, 1591-1602. Integrinâ€Targeting Knottin Peptide–Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation. Angewandte Chemie - International Edition, 2016, 55, 9894-9897.	2.0 4.0 13.8	0 6 22 61
85 86 87 88 88	Ginkgo biloba., 2016,, 1901-1904. Integrinâ€Targeting Knottin Peptide–Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation. Angewandte Chemie, 2016, 128, 10048-10051. Sequential culture on biomimetic nanoclay scaffolds forms threeâ€dimensional tumoroids. Journal of Biomedical Materials Research - Part A, 2016, 104, 1591-1602. Integrinâ€Targeting Knottin Peptide–Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation. Angewandte Chemie - International Edition, 2016, 55, 9894-9897. Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells. BMC Genomics, 2016, 17, 1029.	2.0 4.0 13.8 2.8	0 6 22 61 10
85 86 87 88 88 89 90	Ginkgo biloba., 2016, , 1901-1904. Integrinâ€Targeting Knottin Peptide–Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation. Angewandte Chemie, 2016, 128, 10048-10051. Sequential culture on biomimetic nanoclay scaffolds forms threeâ€dimensional tumoroids. Journal of Biomedical Materials Research - Part A, 2016, 104, 1591-1602. Integrinâ€Targeting Knottin Peptide–Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation. Angewandte Chemie - International Edition, 2016, 55, 9894-9897. Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells. BMC Genomics, 2016, 17, 1029. Herceptin-conjugated temperature-sensitive immunoliposomes encapsulating gemcitabine for breast cancer. Archives of Pharmacal Research, 2016, 39, 350-358.	2.0 4.0 13.8 2.8 6.3	0 6 22 61 10 19
85 86 87 88 89 90	Ginkgo biloba., 2016, , 1901-1904. Integrinâ€Targeting Knottin Peptide–Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation. Angewandte Chemie, 2016, 128, 10048-10051. Sequential culture on biomimetic nanoclay scaffolds forms threeâ€dimensional tumoroids. Journal of Biomedical Materials Research - Part A, 2016, 104, 1591-1602. Integrinâ€Targeting Knottin Peptide–Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation. Angewandte Chemie - International Edition, 2016, 55, 9894-9897. Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells. BMC Genomics, 2016, 17, 1029. Herceptin-conjugated temperature-sensitive immunoliposomes encapsulating gemcitabine for breast cancer. Archives of Pharmacal Research, 2016, 39, 350-358. Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells. Pharmaceutical Research, 2016, 33, 1628-1637.	2.0 4.0 13.8 2.8 6.3 3.5	0 6 22 61 10 19
85 86 87 88 89 90 91 91	Ginkgo biloba., 2016, , 1901-1904. Integrinâ@Targeting Knottin Peptideâ@"Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation. Angewandte Chemie, 2016, 128, 10048-10051. Sequential culture on biomimetic nanoclay scaffolds forms threeâ@dimensional tumoroids. Journal of Biomedical Materials Research - Part A, 2016, 104, 1591-1602. Integrinâ@Targeting Knottin Peptideâ@"Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation. Angewandte Chemie - International Edition, 2016, 55, 9894-9897. Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells. BMC Genomics, 2016, 17, 1029. Herceptin-conjugated temperature-sensitive immunoliposomes encapsulating gemcitabine for breast cancer. Archives of Pharmacal Research, 2016, 39, 350-358. Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells. Pharmaceutical Research, 2016, 33, 1628-1637. Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. Biomaterials, 2016, 96, 47-62.	2.0 4.0 13.8 2.8 6.3 3.5 11.4	0 6 22 61 10 19 31 31

#	Article	IF	CITATIONS
94	PEGylated squalenoyl-gemcitabine nanoparticles for the treatment ofÂglioblastoma. Biomaterials, 2016, 105, 136-144.	11.4	55
95	Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs. Chemical Reviews, 2016, 116, 14379-14455.	47.7	265
96	Exploring the Potent Inhibition of CTP Synthase by Gemcitabineâ€5′â€Triphosphate. ChemBioChem, 2016, 17, 2240-2249.	2.6	19
97	Pixantrone–rituximab versus gemcitabine–rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma. Future Oncology, 2016, 12, 1759-1768.	2.4	16
98	Development of gelatin nanoparticles conjugated with phytohemagglutinin erythroagglutinating loaded with gemcitabine for inducing apoptosis in non-small cell lung cancer cells. Journal of Materials Chemistry B, 2016, 4, 2444-2454.	5.8	18
99	Assessment of cytotoxic damage induced by irradiation combined with hyperthermia and Gemcitabine on cultured glioblastoma spheroid cells. Radiation Physics and Chemistry, 2016, 120, 44-48.	2.8	5
100	Multifunctional platinumâ€based nanoparticles for biomedical applications. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2017, 9, e1410.	6.1	50
101	Gemcitabine Based Peptide Conjugate with Improved Metabolic Properties and Dual Mode of Efficacy. Molecular Pharmaceutics, 2017, 14, 674-685.	4.6	19
102	Influence of graphene-oxide nanosheets impregnation on properties of sterculia gum-polyacrylamide hydrogel formed by radiation induced polymerization. International Journal of Biological Macromolecules, 2017, 99, 699-712.	7.5	37
103	Gemcitabine Integrated Nano-Prodrug Carrier System. Bioconjugate Chemistry, 2017, 28, 1491-1498.	3.6	14
104	Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate. Pharmacogenomics, 2017, 18, 911-925.	1.3	18
105	Gene Expression and Methylation Analyses Suggest DCTD as a Prognostic Factor in Malignant Glioma. Scientific Reports, 2017, 7, 11568.	3.3	16
106	Fluorinated nucleosides as an important class of anticancer and antiviral agents. Future Medicinal Chemistry, 2017, 9, 1809-1833.	2.3	60
107	Engineering gold-based radiosensitizers for cancer radiotherapy. Materials Horizons, 2017, 4, 817-831.	12.2	173
108	Phase I study of veliparib in combination with gemcitabine. Cancer Chemotherapy and Pharmacology, 2017, 80, 631-643.	2.3	11
109	Severe acute toxicity following gemcitabine administration: A report of four cases with cytidine deaminase polymorphisms evaluation. Oncology Letters, 2017, 15, 1912-1916.	1.8	11
110	Fabrication and Cytotoxicity of Gemcitabine-Functionalized Magnetite Nanoparticles. Molecules, 2017, 22, 1080.	3.8	34
111	Silver nanoparticles enhance the apoptotic potential of gemcitabine in human ovarian cancer cells: combination therapy for effective cancer treatment. International Journal of Nanomedicine, 2017, Volume 12, 6487-6502.	6.7	112

#	ARTICLE	IF	CITATIONS
112	Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer. European Journal of Pharmaceutical Sciences, 2018, 115, 296-303.	4.0	12
113	Hyaluronic Acid-Modified Micelles Encapsulating Gem-C ₁₂ and HNK for Glioblastoma Multiforme Chemotherapy. Molecular Pharmaceutics, 2018, 15, 1203-1214.	4.6	24
114	The 4-N-acyl and 4-N-alkyl gemcitabine analogues with silicon-fluoride-acceptor: Application to 18F-Radiolabeling. European Journal of Medicinal Chemistry, 2018, 148, 314-324.	5.5	11
115	Sensitive analysis and pharmacokinetic study of a novel gemcitabine carbamate prodrug and its active metabolite gemcitabine in rats using LC-ESI-MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1083, 249-257.	2.3	5
116	Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation. Pathology and Oncology Research, 2018, 24, 407-417.	1.9	5
117	Gemcitabine and glioblastoma: challenges and current perspectives. Drug Discovery Today, 2018, 23, 416-423.	6.4	40
118	Formulation and Pharmacokinetics of HSA-core and PLGA-shell Nanoparticles for Delivering Gemcitabine. AAPS PharmSciTech, 2018, 19, 812-819.	3.3	6
119	Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo. International Journal of Oncology, 2018, 52, 851-860.	3.3	1
120	Therapeutic use of fluorinated nucleosides – progress in patents. Pharmaceutical Patent Analyst, 2018, 7, 277-299.	1.1	8
121	Silencing of TRPM8 inhibits aggressive tumor phenotypes and enhances gemcitabine sensitivity in pancreatic cancer. Pancreatology, 2018, 18, 935-944.	1.1	23
122	Gemcitabine analogues with 4- <i>N</i> -alkyl chain modified with fluoromethyl ketone group. Nucleosides, Nucleotides and Nucleic Acids, 2018, 37, 248-260.	1.1	2
123	Hypoxia-induced autophagy promotes gemcitabine resistance in human bladder cancer cells through hypoxia-inducible factor 11± activation. International Journal of Oncology, 2018, 53, 215-224.	3.3	40
124	Fe3O4 Nanoparticles in Targeted Drug/Gene Delivery Systems. Materials, 2018, 11, 324.	2.9	169
125	Gemcitabine-Incorporated G-Quadruplex Aptamer for Targeted Drug Delivery into Pancreas Cancer. Molecular Therapy - Nucleic Acids, 2018, 12, 543-553.	5.1	68
126	Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work. European Journal of Medicinal Chemistry, 2019, 182, 111602.	5.5	47
127	Synthesis and in vitro anticancer activity of new gemcitabine-nucleoside analogue dimers containing methyltriazole or ester-methyltriazole linker. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2587-2594.	2.2	5
128	<p>Harmine suppresses the proliferation of pancreatic cancer cells and sensitizes pancreatic cancer to gemcitabine treatment</p> . OncoTargets and Therapy, 2019, Volume 12, 4585-4593.	2.0	31
129	pH-Responsive and Gemcitabine-Containing DNA Nanogel To Facilitate the Chemodrug Delivery. ACS Applied Materials & Interfaces, 2019, 11, 41082-41090.	8.0	41

#	Article	IF	CITATIONS
130	Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data. World Journal of Surgical Oncology, 2019, 17, 185.	1.9	29
131	Everything in Moderation: Lessons Learned by Exploiting Moderate Replication Stress in Cancer. Cancers, 2019, 11, 1320.	3.7	16
132	Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety. Molecules, 2019, 24, 1855.	3.8	68
133	Application of plasma jet to the inhibition of the proliferation of hepatic malignant cells via reactive oxygen species generation. Plasma Processes and Polymers, 2019, 16, 1800173.	3.0	7
134	Interaction of tumor-associated macrophages and cancer chemotherapy. OncoImmunology, 2019, 8, e1596004.	4.6	205
135	The phenotype of target pancreatic cancer cells influences cell death by magnetic hyperthermia with nanoparticles carrying gemicitabine and the pseudo-peptide NucAnt. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 20, 101983.	3.3	30
136	In Silico Modeling of FDA-Approved Drugs for Discovery of Anti-Cancer Agents: A Drug-Repurposing Approach. , 2019, , 577-608.		6
137	Development of Asialoglycoprotein Receptor-Targeted Nanoparticles for Selective Delivery of Gemcitabine to Hepatocellular Carcinoma. Molecules, 2019, 24, 4566.	3.8	42
138	Role of sphingomyelin on the interaction of the anticancer drug gemcitabine hydrochloride with cell membrane models. Colloids and Surfaces B: Biointerfaces, 2020, 196, 111357.	5.0	14
139	Targeted Therapy of Hepatocellular Carcinoma Using Gemcitabine-Incorporated GPC3 Aptamer. Pharmaceutics, 2020, 12, 985.	4.5	8
140	Engineering and combining oncolytic measles virus for cancer therapy. Cytokine and Growth Factor Reviews, 2020, 56, 39-48.	7.2	35
142	The synergistic tumor growth-inhibitory effect of probiotic Lactobacillus on transgenic mouse model of pancreatic cancer treated with gemcitabine. Scientific Reports, 2020, 10, 20319.	3.3	45
143	Lactobacillus Attenuate the Progression of Pancreatic Cancer Promoted by Porphyromonas Gingivalis in K-rasG12D Transgenic Mice. Cancers, 2020, 12, 3522.	3.7	29
144	Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer. European Journal of Pharmacology, 2020, 888, 173486.	3.5	30
145	Applications of Minimally Invasive Nanomedicine-Based Therapies in 3D in vitro Cancer Platforms. Synthesis Lectures on Materials and Optics, 2020, 1, 1-109.	0.2	0
146	Biotin-Decorated PAMAM G4.5 Dendrimer Nanoparticles to Enhance the Delivery, Anti-Proliferative, and Apoptotic Effects of Chemotherapeutic Drug in Cancer Cells. Pharmaceutics, 2020, 12, 443.	4.5	30
147	Temozolomide, Gemcitabine, and Decitabine Hybrid Nanoconjugates: From Design to Proof-of-Concept (PoC) of Synergies toward the Understanding of Drug Impact on Human Glioblastoma Cells. Journal of Medicinal Chemistry, 2020, 63, 7410-7421.	6.4	17
148	Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma. International Immunopharmacology, 2020, 86, 106694.	3.8	18

#	Article	IF	CITATIONS
149	A novel drug repurposing approach for non-small cell lung cancer using deep learning. PLoS ONE, 2020, 15, e0233112.	2.5	23
150	Investigation of conformational structures of gemcitabine and its 2′,2′-difluoro 2′-deoxy derivatives: A computational study. Computational and Theoretical Chemistry, 2020, 1177, 112727.	2.5	0
151	Encapsulation of gemcitabine in RGD-modified nanoliposomes improves breast cancer inhibitory activity. Pharmaceutical Development and Technology, 2020, 25, 640-648.	2.4	9
152	Ribonucleotide reductase inhibitors suppress <scp>SAMHD</scp> 1 ara― <scp>CTP</scp> ase activity enhancing cytarabine efficacy. EMBO Molecular Medicine, 2020, 12, e10419.	6.9	35
153	Anti-recurrence/metastasis and chemosensitization therapy with thioredoxin reductase-interfering drug delivery system. Biomaterials, 2020, 249, 120054.	11.4	36
154	Squalenoyl-gemcitabine/edelfosine nanoassemblies: Anticancer activity in pediatric cancer cells and pharmacokinetic profile in mice. International Journal of Pharmaceutics, 2020, 582, 119345.	5.2	8
155	Modulation of Cancer-Associated Fibrotic Stroma by An Integrin $\hat{1}\pm v\hat{1}^2$ 3 Targeting Protein for Pancreatic Cancer Treatment. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 161-179.	4.5	20
157	Nanotechnology improves the therapeutic efficacy of gemcitabine against a human hepatocellular carcinoma cell line and minimizes its in vivo side effects. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 631-643.	3.0	8
158	Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I. Expert Opinion on Drug Delivery, 2021, 18, 73-102.	5.0	13
159	Multifunctional Applications of Engineered Extracellular Vesicles in the Treatment of Cancer. Endocrinology, 2021, 162, .	2.8	16
160	Mechanisms of resistance to chemotherapy in non-small cell lung cancer. Archives of Pharmacal Research, 2021, 44, 146-164.	6.3	62
161	Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery. Pharmaceutics, 2021, 13, 326.	4.5	54
163	Ellagic Acid Resensitizes Gemcitabine-Resistant Bladder Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition and Gemcitabine Transporters. Cancers, 2021, 13, 2032.	3.7	11
164	Aptamers in biomedicine: Selection strategies and recent advances. Electrochimica Acta, 2021, 376, 137994.	5.2	61
165	Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?. Translational Oncology, 2021, 14, 101056.	3.7	17
166	Targeting nucleotide metabolism as the nexus of viral infections, cancer, and the immune response. Science Advances, 2021, 7, .	10.3	47
167	A Prospective, Phase I/II, Open-Label Pilot Trial to Assess the Safety of Hyperthermic Intraperitoneal Chemotherapy After Oncological Resection of Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 9086-9095.	1.5	5
168	Determining Chemotherapy Agents in Saliva through Spectrometry and Chromatography Methods Correlated with Periodontal Status in Oncology Patients. Applied Sciences (Switzerland), 2021, 11, 5984.	2.5	2

#	Article	IF	CITATIONS
169	Therapeutic potential of thymoquinone in combination therapy against cancer and cancer stem cells. World Journal of Clinical Oncology, 2021, 12, 522-543.	2.3	13
170	Axially slanted laser illumination scheme for direct and accurate Raman spectroscopic determination of gemcitabine concentration in freeze-dried gemcitabine injection powder housed in a glass container. Analytica Chimica Acta, 2021, 1175, 338746.	5.4	3
171	Gemcitabine Direct Electrochemical Detection from Pharmaceutical Formulations Using a Boron-Doped Diamond Electrode. Pharmaceuticals, 2021, 14, 912.	3.8	8
172	Injectable Micelle-Incorporated Hydrogels for the Localized Chemo-Immunotherapy of Breast Tumors. ACS Applied Materials & Interfaces, 2021, 13, 46270-46281.	8.0	11
173	The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity. Cells, 2021, 10, 2382.	4.1	29
174	Building and behavior of a pH-stimuli responsive chitosan nanoparticles loaded with folic acid conjugated gemcitabine silver colloids in MDA-MB-453 metastatic breast cancer cell line and pharmacokinetics in rats. European Journal of Pharmaceutical Sciences, 2021, 165, 105938.	4.0	12
175	Cashing in on ferroptosis against tumor cells: Usher in the next chapter. Life Sciences, 2021, 285, 119958.	4.3	14
176	The intratumoral microbiome: Characterization methods and functional impact. Cancer Letters, 2021, 522, 63-79.	7.2	20
177	Epidermal growth factor receptor promotes tumor progression and contributes to gemcitabine resistance in osteosarcoma. Acta Biochimica Et Biophysica Sinica, 2021, 53, 317-324.	2.0	13
178	Intravesically instilled gemcitabine-induced lung injury in a patient with invasive urothelial carcinoma: A case report. World Journal of Clinical Cases, 2020, 8, 4652-4659.	0.8	1
179	Gemcitabine Functions Epigenetically by Inhibiting Repair Mediated DNA Demethylation. PLoS ONE, 2010, 5, e14060.	2.5	46
180	Gemcitabine Eliminates Double Minute Chromosomes from Human Ovarian Cancer Cells. PLoS ONE, 2013, 8, e71988.	2.5	40
181	Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and 212Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model. PLoS ONE, 2016, 11, e0159904.	2.5	14
182	Antitumor activity of gemcitabine against high-grade meningioma in vitro and in vivo. Oncotarget, 2017, 8, 90996-91008.	1.8	17
183	Small Molecular Gemcitabine Prodrugs for Cancer Therapy. Current Medicinal Chemistry, 2020, 27, 5562-5582.	2.4	26
184	The Chemical Methods of Disulfide Bond Formation and Their Applications to Drug Conjugates. Current Organic Chemistry, 2020, 23, 2802-2821.	1.6	2
185	Nanomedicine: A Promising Avenue for the Development of Effective Therapy for Breast Cancer. Current Cancer Drug Targets, 2020, 20, 603-615.	1.6	4
186	Characterization of Gemcitabine Loaded Polyhydroxybutyrate Coated Magnetic Nanoparticles for Targeted Drug Delivery. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 1233-1240.	1.7	10

#	Article	IF	CITATIONS
187	Design, Development and Characterization of Solid Lipid Nanoparticles of Gemcitabine Hydrochloride. Drug Delivery Letters, 2012, 2, 262-269.	0.5	2
189	Application of ²¹² Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation. AIMS Medical Science, 2015, 2, 228-245.	0.4	46
190	Metastatic brain tumor from urothelial carcinoma of the prostatic urethra. , 2016, 7, S488.		7
191	Gemcitabine Degradation in Whole Blood from Humans, Dogs, Cats, and Horses. Journal of Veterinary Science & Technology, 2012, 03, .	0.3	1
192	Active Hexose Correlated Compound (AHCC) Alleviates Gemcitabine-Induced Hematological Toxicity in Non-Tumor-Bearing Mice. International Journal of Clinical Medicine, 2012, 03, 361-367.	0.2	1
193	Role of Akt signaling in resistance to DNA-targeted therapy. World Journal of Clinical Oncology, 2016, 7, 352.	2.3	48
194	No Relationship between the Amount of DNA Damage and the Level of hMLH1 and RASSF1A Gene Expression in Bladder Cancer Cells Treated with Cisplatin and Gemcitabine. Asian Pacific Journal of Cancer Prevention, 2013, 14, 5941-5948.	1.2	5
195	Integrative Meta-Analysis of Multiple Gene Expression Profiles in Acquired Gemcitabine-Resistant Cancer Cell Lines to Identify Novel Therapeutic Biomarkers. Asian Pacific Journal of Cancer Prevention, 2015, 16, 2793-2800.	1.2	2
196	Targeting Notch to Maximize Chemotherapeutic Benefits: Rationale, Advanced Strategies, and Future Perspectives. Cancers, 2021, 13, 5106.	3.7	16
197	Photoacoustic imaging of elevated glutathione in models of lung cancer for companion diagnostic applications. Nature Chemistry, 2021, 13, 1248-1256.	13.6	93
198	An Engineered Specificity of Anti-Neoplastic Agent Loaded Magnetic Nanoparticles for the Treatment of Breast Cancer. Polymers, 2021, 13, 3623.	4.5	3
204	Gemcitabine and carboplatin in metastatic nonsmall cell lung cancer: Experience from a tertiary cancer center in South India. Indian Journal of Cancer, 2017, 54, 169.	0.2	0
205	Recombinant deoxyribonucleoside kinase from Drosophila melanogaster can improve gemcitabine based combined gene/chemotherapy for targeting cancer cells. Bosnian Journal of Basic Medical Sciences, 2019, 19, 342-349.	1.0	0
206	Compendium of Mechanistic Insights of Distinct Conventional Anticancer Therapies and Their Grievous Toxicities. , 2020, , 111-136.		0
207	Chemoprotective and chemosensitizing effects of apigenin on cancer therapy. Cancer Cell International, 2021, 21, 574.	4.1	28
208	Polysaccharide Nanogels for the Delivery of Gemcitabine Hydrochloride. ACS Applied Polymer Materials, 2021, 3, 6345-6358.	4.4	1
209	Fixed-dose-rate administration of gemcitabine in cancer-bearing cats: A pilot study. Canadian Veterinary Journal, 2016, 57, 1149-1155.	0.0	0
210	Fabrication of dopamine conjugated with protein @metal organic framework for targeted drug delivery: A biocompatible pH-Responsive nanocarrier for gemcitabine release on MCF‑7 human breast cancer cells. Bioorganic Chemistry, 2022, 118, 105467.	4.1	13

#	Article	IF	CITATIONS
211	Imiquimod-gemcitabine nanoparticles harness immune cells to suppress breast cancer. Biomaterials, 2022, 280, 121302.	11.4	23
212	A self-assembling prodrug nanosystem to enhance metabolic stability and anticancer activity of gemcitabine. Chinese Chemical Letters, 2022, 33, 2481-2485.	9.0	13
213	Severe Generalized Weakness, Paraplegia following administration of Oxaliplatin in a patient with refractory T-cell non-Hodgkin lymphoma: A case report. Journal of Oncology Pharmacy Practice, 2022, , 107815522110735.	0.9	1
214	Investigation of the adsorption properties of gemcitabine anticancer drug with metal-doped boron nitride fullerenes as a drug-delivery carrier: a DFT study. RSC Advances, 2022, 12, 2873-2887.	3.6	31
215	Aptamers: an emerging navigation tool of therapeutic agents for targeted cancer therapy. Journal of Materials Chemistry B, 2021, 10, 20-33.	5.8	19
217	Re-Discovery of Pyrimidine Salvage as Target in Cancer Therapy. Cells, 2022, 11, 739.	4.1	19
218	Enantioâ€, Diastereo―and Regioselective Synthesis of Chiral Cyclic and Acyclic <i>gem</i> â€Difluoromethylenes by Palladiumâ€Catalyzed [4+2] Cycloaddition. Angewandte Chemie, 2022, 134, .	2.0	2
219	Phyto-targeting the CEMIP expression as a strategy to prevent pancreatic cancer metastasis. Current Pharmaceutical Design, 2022, 28, .	1.9	4
220	Enantioâ€; Diastereo―and Regioselective Synthesis of Chiral Cyclic and Acyclic <i>gem</i> â€Difluoromethylenes by Palladiumâ€Catalyzed [4+2] Cycloaddition. Angewandte Chemie - International Edition, 2022, 61, .	13.8	16
221	Recent advances in organic and polymeric carriers for local tumor chemo-immunotherapy. Science China Technological Sciences, 2022, 65, 1011-1028.	4.0	7
223	Aptamer–Gemcitabine Conjugates with Enzymatically Cleavable Linker for Targeted Delivery and Intracellular Drug Release in Cancer Cells. Pharmaceuticals, 2022, 15, 558.	3.8	7
224	Tumor micro-environment targeted collagenase-modified albumin nanoparticles for improved drug delivery. Journal of Drug Delivery Science and Technology, 2022, 71, 103366.	3.0	6
225	Immune-Related Protein Interaction Network in Severe COVID-19 Patients toward the Identification of Key Proteins and Drug Repurposing. Biomolecules, 2022, 12, 690.	4.0	3
226	Dissolution and Biological Assessment of Cancer-Targeting Nano-ZIF-8 in Zebrafish Embryos. ACS Biomaterials Science and Engineering, 2022, 8, 2445-2454.	5.2	8
227	Broader and safer clinically-relevant activities of pentadecanoic acid compared to omega-3: Evaluation of an emerging essential fatty acid across twelve primary human cell-based disease systems. PLoS ONE, 2022, 17, e0268778.	2.5	12
228	SERS-Based Ultralow Concentration Detection of Anticancer Gemcitabine Using Size-Controlled Silver Nanoparticles. Arabian Journal for Science and Engineering, 2022, 47, 7197-7205.	3.0	2
229	Targeted Inhibition of O-Linked Î ² -N-Acetylglucosamine Transferase as a Promising Therapeutic Strategy to Restore Chemosensitivity and Attenuate Aggressive Tumor Traits in Chemoresistant Urothelial Carcinoma of the Bladder. Biomedicines, 2022, 10, 1162.	3.2	1
230	Diclofenac: A Nonsteroidal Anti-Inflammatory Drug Inducing Cancer Cell Death by Inhibiting Microtubule Polymerization and Autophagy Flux. Antioxidants, 2022, 11, 1009.	5.1	10

#	Article	IF	CITATIONS
231	Strategies for the Synthesis of Fluorinated Nucleosides, Nucleotides and Oligonucleotides. Chemical Record, 2022, 22, .	5.8	8
232	HIF-1-dependent heme synthesis promotes gemcitabine resistance in human non-small cell lung cancers via enhanced ABCB6 expression. Cellular and Molecular Life Sciences, 2022, 79, .	5.4	8
234	Implication of methylselenocysteine in combination chemotherapy with gemcitabine for improved anticancer efficacy. European Journal of Pharmaceutical Sciences, 2022, 176, 106238.	4.0	6
235	Design, synthesis and antitumor activity study of a gemcitabine prodrug conjugated with a HDAC6 inhibitor. Bioorganic and Medicinal Chemistry Letters, 2022, 72, 128881.	2.2	5
236	Novel intravesical therapeutics inÂthe treatment of non-muscle invasive bladder cancer: HorizonÂscanning. Frontiers in Surgery, 0, 9, .	1.4	5
237	Synthesis of Functionalized Five-Membered Heterocycles from Epoxides: A Hydrogen-Bond Donor Catalytic Approach. Journal of Organic Chemistry, 2023, 88, 12872-12883.	3.2	3
238	Transcriptional patterns reveal tumor histologic heterogeneity and immunotherapy response in lung adenocarcinoma. Frontiers in Immunology, 0, 13, .	4.8	0
239	Insight into the interplay between mitochondria-regulated cell death and energetic metabolism in osteosarcoma. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	8
240	System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma. Journal of Translational Medicine, 2022, 20, .	4.4	38
241	Combined Therapy for the Treatment of Cancer. , 2022, , 27-55.		0
242	Peptide-Drug Conjugates: A New Hope for Cancer Management. Molecules, 2022, 27, 7232.	3.8	28
243	Augmenting chemotherapy with low-dose decitabine through an immune-independent mechanism. JCI Insight, 2022, 7, .	5.0	3
244	Gemcitabine-induced digital ischaemia in a patient with metastatic breast cancer. BMJ Case Reports, 2022, 15, e252083.	0.5	1
245	Barriers and opportunities for gemcitabine in pancreatic cancer therapy. American Journal of Physiology - Cell Physiology, 2023, 324, C540-C552.	4.6	16
246	Candidate drugs associated with sensitivity of cancer cell lines with <i>DLST</i> amplification or high mRNA levels. Oncotarget, 2023, 14, .	1.8	0
247	Gemcitabine alters sialic acid binding of the glycocalyx and induces inflammatory cytokine production in cultured endothelial cells. Medical Molecular Morphology, 0, , .	1.0	1
248	Gold Nanoparticles Synthesized by an Aqueous Extract of Codium tomentosum as Potential Antitumoral Enhancers of Gemcitabine. Marine Drugs, 2023, 21, 20.	4.6	5
249	Examining the efficacy of localised gemcitabine therapy for the treatment of pancreatic cancer using a hybrid agent-based model. PLoS Computational Biology, 2023, 19, e1010104.	3.2	2

		CITATION REPORT		
#	Article		IF	CITATIONS
250	Targeted Therapies Used in the Treatment of Nonâ \in Small-Cell Lung Cancer: An Overview.	, 2023, , 111-158.		0
251	Performance evaluation of the HPLC diode array and evaporative light scattering detection implementation of dose-banded gemcitabine infusion bags. European Journal of Hospital Phejhpharm-2022-003540.	for the harmacy, 0, ,	1.1	0
252	Gemcitabine-Induced Myositis in a Luminal B Breast Cancer patient: A Case Report. Clinical Insights: Case Reports, 2023, 16, 117954762311562.	Medicine	0.7	1
253	Drug–Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics. Intern Journal of Molecular Sciences, 2023, 24, 2885.	ational	4.1	5
254	DNA Nanogel for Cancer Therapy. Advanced Therapeutics, 2023, 6, .		3.2	5
255	Drug Delivery Systems for Localized Cancer Combination Therapy. ACS Applied Bio Materia 934-950.	ls, 2023, 6,	4.6	10
256	Application of magnetic solid-phase extraction for sensitive determination of anticancer dru urine by means of diamino benzidine tetrachlorohydrate modified magnetic nanoparticles. Pharmacological Reports, 2023, 75, 456-464.	ıgs in	3.3	3
257	Synthetic cytotoxic drugs as cancer chemotherapeutic agents. , 2023, , 499-537.			2
259	Biomedical,clinical and environmental applications of platinum-based nanohybrids: An upda Environmental Research, 2023, 231, 116148.	ted review.	7.5	9
260	In Silico Pharmacology and Drug Repurposing Approaches. , 2023, , 253-281.			0
261	Shielding and nurturing: Fibronectin as a modulator of cancer drug resistance. Journal of Ce Physiology, 0, , .	llular	4.1	0
262	ZERDEćALIN BİYOAKTİF BİLEŞİĞİ KURKUMİN, GEMSİTABİNİN PROSTAT k ĖZELLİĞİNİ GELİŞTİREBİLİR. Ankara Universitesi Eczacilik Fakultesi Dergisi, 2	(ANSERİ HÜCRELEI 2023, 47, 3-3.	RİNDEKÄ	° ANTİ-MA
263	Mycoplasma infection of cancer cells enhances anti-tumor effect of oxidized methylcytidine Biochemical and Biophysical Research Communications, 2023, 672, 193-200.	?S.	2.1	0
264	ZnO nanoflowers modified pencil graphite electrode for voltammetric DNA detection and investigation of Gemcitabine–DNA interaction. Materials Chemistry and Physics, 2023, 30	07, 128117.	4.0	3
265	A metalâ€dependent conformational change provides a structural basis for the inhibition of synthase by gemcitabineâ€5′â€triphosphate. Protein Science, 2023, 32, .	f CTP	7.6	1
266	Switching Regioselectivity in the Asymmetric Bromocyclization of Difluoroalkenes Catalyze Chiral Bisphosphine Oxide. Synlett, 2023, 34, 2476-2480.	d by a	1.8	1
267	Exploring the Inclusion Complex of an Anticancer Drug with β-Cyclodextrin for Reducing Cy Toward the Normal Human Cell Line by an Experimental and Computational Approach. ACS 8, 29388-29400.	/totoxicity Omega, 2023,	3.5	0
268	JNTX-101, a novel albumin-encapsulated gemcitabine prodrug, is efficacious and operates v caveolin-1-mediated endocytosis. Molecular Therapy - Oncolytics, 2023, 30, 181-192.	ia	4.4	2

#	Article	IF	CITATIONS
269	Nucleoside-based anticancer drugs: Mechanism of action and drug resistance. Biochemical Pharmacology, 2023, 215, 115741.	4.4	4
270	Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients. Cancer Chemotherapy and Pharmacology, 2023, 92, 475-483.	2.3	1
271	Hydrogen peroxide-triggered small molecule theranostics for cancer therapy: A review. AIP Conference Proceedings, 2023, , .	0.4	0
272	p21 promotes gemcitabine tolerance in A549 cells by inhibiting DNA damage and altering the cell cycle. Oncology Letters, 2023, 26, .	1.8	0
273	Hazard assessment of antineoplastic drugs and metabolites using cytotoxicity and genotoxicity assays. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2023, 892, 503704.	1.7	0
274	The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress. Bioconjugate Chemistry, 2023, 34, 1951-2000.	3.6	4
275	Real-world efficacy of adjuvant single-agent intravesical gemcitabine for non-muscle invasive bladder cancer. Expert Opinion on Pharmacotherapy, 2023, 24, 2081-2091.	1.8	2
276	Inhibitory effect of liriopesides B in combination with gemcitabine on human pancreatic cancer cells. Bioorganic Chemistry, 2023, , 106937.	4.1	0
277	The Functional Implications of Broad Spectrum Bioactive Compounds Targeting RNA-Dependent RNA Polymerase (RdRp) in the Context of the COVID-19 Pandemic. Viruses, 2023, 15, 2316.	3.3	0
278	A Sensitive Electrochemical DNA Biosensor for Determination of Anti-Cancer Drug Gemcitabine Based on an AuNPs/MWCNTs/Carbon Paste Electrode. Journal of the Electrochemical Society, 2023, 170, 117510.	2.9	0
279	Biological and clinical significance of the glypican-3 gene in human lung adenocarcinoma: An in silico analysis. Medicine (United States), 2023, 102, e35347.	1.0	0
280	Quantitative Analysis of 2D EXSY NMR Spectra of Strongly Coupled Spin Systems in Transmembrane Exchange. ChemBioChem, 2024, 25, .	2.6	0
281	Electronic spectroscopy of gemcitabine and derivatives for possible dual-action photodynamic therapy applications. Journal of Chemical Physics, 2023, 159, .	3.0	1
282	Computational chemistry of natural product analogues. , 2024, , 395-437.		0
283	A Surprising Repurposing of Central Nervous System Drugs against Squamous Cell Carcinoma of the Bladder, UM-UC-5. Pharmaceutics, 2024, 16, 212.	4.5	0
285	Catalysts of Healing: A Symphony of Synthesis and Clinical Artistry in Small-Molecule Agents for Breast Cancer Alleviation. Molecules, 2024, 29, 1166.	3.8	Ο
286	PRMT1 promotes pancreatic cancer development and resistance to chemotherapy. Cell Reports Medicine, 2024, 5, 101461.	6.5	0
287	Development of pH and thermo-responsive smart niosomal carriers for delivery of gemcitabine to the breast cancer cells. Emergent Materials, 0, , .	5.7	0

#	Article	IF	CITATIONS
288	Gemcitabine Modulates HLA-I Regulation to Improve Tumor Antigen Presentation by Pancreatic Cancer Cells. International Journal of Molecular Sciences, 2024, 25, 3211.	4.1	0